HCP
TEVA icon

Hexagon Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Hexagon Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,032
Closed -$15.9K – 1547
2025
Q1 		$15.9K Sell
1,032
-106
-9% -$1.89K ﹤0.01% 824
2024
Q4 		$25.1K Buy
1,138
+310
+37% +$5.64K ﹤0.01% 707
2024
Q3 		$14.9K Buy
828
+70
+9% +$1.23K ﹤0.01% 805
2024
Q2 		$12.3K Sell
758
-10
-1% -$154 ﹤0.01% 810
2024
Q1 		$10.8K Buy
768
+10
+1% +$126 ﹤0.01% 839
2023
Q4 		$7.91K Buy
758
+528
+230% +$4.93K ﹤0.01% 875
2023
Q3 		$2.35K Sell
230
-2
-0.9% -$19 ﹤0.01% 1042
2023
Q2 		$1.75K Buy
232
+34
+17% +$276 ﹤0.01% 1103
2023
Q1 		$1.75K Sell
198
-126
-39% -$1.25K ﹤0.01% 1092
2022
Q4 		$2.96K Buy
324
+14
+5% +$122 ﹤0.01% 1009
2022
Q3 		$3K Buy
310
+116
+60% +$1.03K ﹤0.01% 1054
2022
Q2 		$1K Buy
194
+108
+126% +$941 ﹤0.01% 1131
2022
Q1 		$1K Hold
86
– – ﹤0.01% 890
2021
Q4 		$1K Hold
86
– – ﹤0.01% 826
2021
Q3 		$1K Hold
86
– – ﹤0.01% 827
2021
Q2 		$1K Hold
86
– – ﹤0.01% 788
2021
Q1 		$0 Hold
86
– – ﹤0.01% 787
2020
Q4 		$0 Hold
86
– – ﹤0.01% 751
2020
Q3 		$0 Buy
+86
New +$910 ﹤0.01% 721

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hexagon Capital Partners's TEVA Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 1,032 shares — an estimated $15.9K sold.

Hexagon Capital Partners first reported a position in TEVA in Q3 2020 and held it in 19 quarters. The position peaked at $25.1K in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 1,032 Teva Pharmaceuticals shares in Q2 2025, an estimated $15.9K.
  • Hexagon Capital Partners first reported a position in Teva Pharmaceuticals in Q3 2020 and held it in 19 quarters.
  • Hexagon Capital Partners's Teva Pharmaceuticals position peaked at $25.1K in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.